ClinicalTrials.gg
CompletedNCT00770874Updated Jun 21, 2019Results posted

Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer

A Phase 3 interventional study of S-1 + Cisplatin (arm A) and Cisplatin (arm B) in Cervical Cancer, sponsored by Taiho Pharmaceutical Co., Ltd.. Completed at 4 sites in 3 countries. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-06-21.

Sponsored by Taiho Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
375
Allocation
Randomized
Ages
20 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies in Uterine Cervical Neoplasms with a site in Japan — 15 open to participants now, 23 under way, 3 of them phase 3. Uterine Cervical Neoplasms · Japan.

Enrollment
24th of 45
375 · median 384
Started
2008
the only one that year
Phase 3
15 of 49
2 open now
Registered
6th of 49
by date

Among the 49 studies in Uterine Cervical Neoplasms with a site in Japan, this one is the 24th largest by enrollment of the 45 interventional ones that give a count, is the only one that started in 2008, is one of 15 in phase 3, and was the 6th registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

15 of the 49 studies in Uterine Cervical Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 20 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Uterine Cervical Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

This study is an open-label, multicenter, multinational, two-arm, parallel randomized Phase 3 study evaluating the efficacy and safety of S-1+Cisplatin versus single-agent Cisplatin in patients with stage IVB, recurrent or persistent carcinoma of the cervix.

Read the detailed description

Japanese phase II study of S-1 in cervical cancer suggested promising response rate and good tolerability. Since recommended chemotherapy for metastatic or recurrent cervical carcinoma is either single-agent Cisplatin or Cisplatin-based combination chemotherapy, this is designed to evaluate the efficacy and safety of S-1 in combination with Cisplatin compared with single-agent Cisplatin.

03

Conditions studied

  • Cervical Cancer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with proven cervical carcinoma (All histological subtype will be included).
  • Patients who have stage IVB, recurrent or persistent disease.
  • Patients who are not amenable to curative treatment with surgery and/or radiotherapy.
  • Patients who have not received chemotherapy or chemoradiotherapy after diagnosis of recurrent, persistent, or stage IVB disease.
  • If the patient have received chemotherapy, radiotherapy or chemoradiotherapy as previous treatment, following interval must have elapsed from the last administration of treatment:

    1. Chemotherapy: 21 days
    2. Radiotherapy: 21 days*
    3. Chemoradiotherapy: 42 days*

If there have been residual disease in previously irradiated field and without disease progression since the (chemo) radiotherapy, 90 days must have elapsed after the last administration of irradiation.

  • Patients who have adequate hematologic, hepatic and renal functions as defined below:

    • : ≥ 8.0 g/dL
    • : ≥ 2,000/mm\^3
    • count: ≥ 100,000/mm\^3
    • Total serum : ≤ 1.5 times the (ULN)
    • (GOT), ALT (GPT): ≤ 2.5 times the ULN. If abnormal values are associated with hepatic : ≤ 5.0 times the ULN
    • Serum creatinine: ≤ ULN or : ≥ 50 ml/min
  • Patients who have an performance status : 0-1.
  • Age: ≥ 20 years old.
  • Patients who can take pills orally.
  • Patients who signed the written consent form.

Exclusion criteria

Exclusion Criteria:

  • Patients who have known to 5-FU or Cisplatin.
  • Patients who are receiving concomitant treatment with drugs interacting with S-1.
  • Patients who are receiving concomitant treatment with drugs interacting with Cisplatin.
  • Patients who were administered other products within 30 days before the initiation of study treatment.
  • Patients who were previously treated with S-1.
  • Patients who had received platinum-containing chemotherapy or chemoradiotherapy and whose disease progressed during the therapy.
  • Patients who suffer from active infection (e.g. fever ≥ 38°C).
  • Patients who have serious complications.
  • Patients with bleeding which requires hemostasis treatment.
  • Patients with bilateral hydronephrosis which cannot be alleviated by ureteral stents or percutaneous drainage.
  • Patients with uncontrolled pleural effusion and/or ascites requiring drainage at least twice a week.
  • Patients with symptomatic or history of brain metastasis.
  • Patients who have unmanageable bowel movement (ex. Watery stool, chronic constipation).
  • Patients with active double cancer.
  • Patients who are pregnant or lactating.
  • Patients who are considered to be inappropriate to the subject of this study by the investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
375 participants (actual)

Study arms

  • Experimental
    1

    S-1 + Cisplatin (arm A)

    Drug: S-1 + Cisplatin (arm A)

  • Active comparator
    2

    Cisplatin (arm B)

    Drug: Cisplatin (arm B)

Interventions

  • DrugS-1 + Cisplatin (arm A)

    Drug pages: Tegafur · Gimeracil · Oxonic Acid · Cisplatin

    S-1 will be administered orally, twice daily from Day 1 through Day 14 followed by a recovery period from Days 15 through Day 21. Initial dose of S-1 will be determined according to the patient's body surface area (80 to 120 mg/day). On Day 1, Cisplatin 50 mg/m2 will be administered intravenously (IV). This regimen is to be repeated every 3 weeks.

  • Cisplatin 50 mg/m2 will be administered intravenously (IV) on Day 1, repeated every 3 weeks.

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Time frame: From the date of randomization to death from any cause, assessed up to 296 events or the end of November 2015, whichever was earlier, each three months

Secondary outcomes

  1. Progression Free Survival, Safety

    Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: About Progression free survival, from the randomization to disease progression or death, whichever came first, assessed up to until primary outcome came each three months, and about safety, from the first treatment to 30 days after the last treatment

07

Results

Posted Jun 21, 2019

Participant flow

375 patients were randomized to Arm A (189) or Arm B (186); of these, 364 patients(188 and 176, respectively) received study treatment. 11 patients (1 and 10, respectively) did not receive allocated intervention because of 'withdrew consent(1 and 6, respectively)' , 'ineligible criteria(3 in Arm B)', or 'investigator's discretion(1 in Arm B)'.

Participant flow — Overall Study
MilestoneS-1 + Cisplatin (Arm A)Cisplatin (Arm B)
Started188176
Completed188176
Not completed00

Outcome measures

PrimaryOverall Survival
Time frame:
From the date of randomization to death from any cause, assessed up to 296 events or the end of November 2015, whichever was earlier, each three months
Reported as:
Median · months
Overall Survival
monthsS-1 + Cisplatin (Arm A)Cisplatin (Arm B)
Overall Survival21.9 (18.6 to 25.8)19.5 (17.0 to 24.3)
Statistical analysis
  • S-1 + Cisplatin (Arm A) · Log Rank · p = 0.125 · Hazard ratio (hr): 0.84 · 95% CI 0.67 to 1.05
SecondaryProgression Free Survival, Safety

Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
About Progression free survival, from the randomization to disease progression or death, whichever came first, assessed up to until primary outcome came each three months, and about safety, from the first treatment to 30 days after the last treatment
Reported as:
Median · months
Progression Free Survival, Safety
monthsS-1 + Cisplatin (Arm A)Cisplatin (Arm B)
Progression Free Survival, Safety7.3 (6.7 to 8.1)4.9 (4.4 to 5.7)
Statistical analysis
  • S-1 + Cisplatin (Arm A) · Log Rank · p = <0.001 · Hazard ratio (hr): 0.62 · 95% CI 0.48 to 0.80

Adverse events

Collected over From the date of the first treatment to 30 days after the last treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
S-1 + Cisplatin (Arm A)7/188 (3.7%)72/188 (38.3%)188/188 (100%)
Cisplatin (Arm B)3/175 (1.7%)34/175 (19.4%)172/175 (98.3%)
Most frequent serious events
Showing 10 of 77
Most frequent serious events
EventS-1 + Cisplatin (Arm A)Cisplatin (Arm B)
Neutrophil count decreasedInvestigations12/1880/175
Haemoglobin decreasedInvestigations10/1885/175
ThrombosisVascular disorders10/1882/175
DiarrhoeaGastrointestinal disorders9/1880/175
Urinary tract infectionInfections and infestations5/1884/175
Platelet count decreasedInvestigations5/1880/175
Ureteric obstructionRenal and urinary disorders5/1882/175
VomitingGastrointestinal disorders4/1880/175
PyrexiaGeneral disorders4/1880/175
Febrile neutropeniaBlood and lymphatic system disorders3/1880/175
Most frequent other events
Showing 10 of 52
Most frequent other events
EventS-1 + Cisplatin (Arm A)Cisplatin (Arm B)
NauseaGastrointestinal disorders153/188134/175
Neutrophil count decreasedInvestigations148/18865/175
Haemoglobin decreasedInvestigations147/18887/175
Decreased appetiteMetabolism and nutrition disorders141/188105/175
FatigueGastrointestinal disorders109/18879/175
VomitingGastrointestinal disorders103/18871/175
DiarrhoeaGastrointestinal disorders94/18851/175
White blood cell count decreasedInvestigations92/18852/175
Platelet count decreasedInvestigations90/18826/175
ConstipationGastrointestinal disorders61/18848/175

Baseline characteristics

A total of 364 (188 in Arm A; 176 in Arm B) received study treatment. Two patients in Arm B were excluded in the efficacy analysis, because of insufficient informed consent, and missing efficacy data.

Age, Continuous
Age, Continuous(years)S-1 + Cisplatin (Arm A)Cisplatin (Arm B)Total
Median55 (27 to 84)52.5 (28 to 81)54 (27 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)S-1 + Cisplatin (Arm A)Cisplatin (Arm B)Total
Female188174362
Male000
Region of Enrollment
Region of Enrollment(participants)S-1 + Cisplatin (Arm A)Cisplatin (Arm B)Total
South Korea5249101
Japan110105215
Taiwan262046
08

Study locations

4 sites
  • Yanagawa Hospital
    Chikushimachi, Yanagawa, Fukuoka 832-0077, Japan
  • Cancer Institute Hospital
    Ariake, Koto-ku, Tokyo 135-8550, Japan
  • Konkuk University Medical Center
    Hwayang-dong, Gwangjin-gu, Seoul 143-729, Korea, Republic of
  • Chang Gung Medical Foundation- Linkou
    Fu-Hsing Saint Kuei Shan Hsiang, TaoYuan Hsien 33305, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Dec 2015 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2019, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2008
First posted
Oct 10, 2008
Start
Sep 2008
Primary completionActual
Dec 2015
CompletionActual
Apr 2016
Results first posted
Jun 21, 2019
Last update
Jun 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00770874
Responsible party
Sponsor
First posted
Oct 10, 2008
Start date
Sep 2008
Primary completion
Dec 2015
Completion
Apr 2016
Results posted
Jun 21, 2019
Last update
Jun 21, 2019

Study contacts

Ken Takizawa, MD
study chair · Cancer Institute Hospital
Toshiharu Kamura, MD
study chair · Yanagawa Hospital
Ting-Chang Chang, MD
study chair · Chang Gung Memorial Hospital
Soon-Beom Kang, MD
study chair · Konkuk University Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tegafur · Gimeracil · Oxonic Acid · Cisplatin

Start the discussion